Re: An alternate theory
''Just reading that makes my head hurt. I can't imagine trying to build that complex set of edits and then looking for a patient sick enough to not care about getting such a wildly complex and likely highly toxic drug.''
Complex problems require complex solutions. As the edits are done to the CAR-T's, it would reduce toxicities along with costs when compared to other treatments that are given systemically. The payloads could be a problem, but both AUTL  and Refuge Bio  seem to have overcome this.
''Someone must think it looks good on paper because so far that is all there is.''
A single armoured (dnTGFB) CAR-T product is being tested in mCRPC. A PhII should start in Q4.